Trials / Withdrawn
WithdrawnNCT04740970
A Study of JNJ-64304500 in Participants With Alopecia Areata
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-64304500 in Patients With Alopecia Areata
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the clinical response of 22 weeks of study intervention with JNJ-64304500, compared with placebo, in participants with moderate to severe alopecia areata (AA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-64304500 | JNJ-64304500 injection will be administered subcutaneously. |
| DRUG | Placebo | Matching placebo injection will be administered subcutaneously. |
Timeline
- Start date
- 2021-03-24
- Primary completion
- 2022-06-02
- Completion
- 2022-07-20
- First posted
- 2021-02-05
- Last updated
- 2021-05-04
Locations
22 sites across 4 countries: United States, Australia, France, Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04740970. Inclusion in this directory is not an endorsement.